Trump's pharmaceutical tariffs could affect some drugmakers more than others

  • President Donald Trump is slated to impose tariffs on pharmaceuticals imported into the U.S. any day now – and they may have a bigger impact on some drugmakers than others. AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned" based on their manufacturing footprint in the U.S. compared to abroad, while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said in a note.